Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
Human research record. Stroke, 2016.
- Human
- 2016
Authorship
Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.
Source: the abstract of PMID 26564102. Checked Verification: Evidence verified by machine against declared source
This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.
Evidence verified by machine against declared source
Key facts
- Design
- Not reported
- System
- Human
- Scale
- A total of 208 patients were enrolled in this study between April 2008 and September 2010.
- Comparator
- Present
- Journal
- Stroke
- Year
- 2016
- PMID
- 26564102
- Verification
- Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
- Full-text availability
- Abstract only
Technical summary
Research question
The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo.
Study design
This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
Participants or experimental system
Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset.
Study scale
A total of 208 patients were enrolled in this study between April 2008 and September 2010.
Intervention or exposure
The study medication was administered once daily for 21 days as an intravenous infusion for 20 minutes, beginning at 24 to 72 hours after stroke onset.
Comparator
This prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study compared the effects of 30 mL Cerebrolysin versus placebo during early rehabilitation after stroke.
Outcomes examined
The primary end point was the Action Research Arm Test score on day 90.
Key findings
The nonparametric effect size on the Action Research Arm Test score on day 90 indicated a large superiority of Cerebrolysin compared with the placebo (Mann–Whitney estimator, 0.71; 95% confidence interval, 0.63–0.79; P<0.0001).
Not reported in the declared source: Methods.
Limitations and uncertainty
Because this study was exploratory and had a relatively small sample size, the results should be confirmed in a large-scale, randomized clinical trial.
Cite
Cite the study
Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.
Muresanu DF, Heiss WD, Hoemberg V et al. Stroke. 2016. PMID 26564102
The study and its abstract belong to their authors and publisher. Cite them for anything the study found.
Report an error
If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.
The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.
The report form runs in the interactive page. Open this record with scripts enabled to send a report.
Corrections on this record
No correction has been recorded for this record.
Method sheet
No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.